Vanguards of Healthcare by Bloomberg Intelligence
Vanguards of Healthcare by Bloomberg Intelligence
Vanguards of Healthcare is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.Social links:
Follow the podcast:
Restor3D Combines AI with 3D Printing to Create Personalized Ortho Solutions
“If you plan, the cases can go much more smoothly. And if you have patient-specific instrumentation, they can go much more quickly” says restor3D’s CEO Kurt Jacobus in this episode of Vanguards of Healthcare. He sat down with BI analyst Matt Henriksson to elaborate on personalized orthopedic implan…
40:30
AstraZeneca’s ASCO Readout on Oncology’s Next Wave
“I think it’s the most exciting period in cancer discovery and development that I’ve experienced over the last 25 years,” says Susan Galbraith, executive vice president of oncology R&D at AstraZeneca. Galbraith joins Bloomberg Intelligence analyst Sam Fazeli fresh from the ASCO conference to unpack…
57:59
Ocular Therapeutix Cuts Blindness Toll
“Forty percent of patients in this country alone in the first year drop out [of current retinal disease treatments] and every one of those patients ends up going blind. By far the most expensive disease in the world is blindness and the reason for that is really quite simple. It’s because the morta…
23:50
IRhythm Pushes a Proactive Approach to Monitoring
“We’re seeing it already to much more of a preventative proactive monitoring to find these things earlier in the patient journeys and help eliminate and prevent and reduce downstream costs,” IRhythm Technologies CEO Quentin Blackford discusses the opportunities of remote monitoring with Bloomberg I…
46:11
Pulse Biosciences Brings Differentiated Nanosecond Technology to PFA
Based on long-term results, “the effectiveness of that nanosecond pulse electric field begins to look as if it is a step function ahead of first generation PFA,” Pulse Biosciences CEO Paul LaViolette says, referring to the next stage of pulsed-field ablation innovation. In this Vanguards of Health…
45:16
RTW’s Rod Wong on Biotech’s Revival and the Global Shift
“I think this is going to be the most eventful ASCO for biotech in a while,” says Dr. Roderick Wong, founder of RTW Investments, referring to the annual meeting of the American Society of Clinical Oncology. Wong joins Bloomberg Intelligence analyst Sam Fazeli on the Vanguards of Health Care podcast…
49:51
Cortica’s Plan to Bring Value-Based Care to Autism
“It’s crazy to think that that would be the expectation in cancer care, yet we expect that of families in autism,” says Neil Hattangadi, CEO and co-founder of Cortica. Hattangadi joins Bloomberg Intelligence analyst Jonathan Palmer to explain why autism care remains so fragmented and how Cortica is…
55:12
Xontogeny's Case for Drug Developers Over Storytellers
“More than half of your time as a public company CEO is devoted to things that are not drug development,” Xontogeny CEO Chris Garabedian says. Garabedian joins Bloomberg Intelligence analyst Sam Fazeli on this episode of the Vanguards of Health Care podcast to explain why he earlier left the track …
52:17
Roivant’s Playbook for Finding Value Others Miss in Biotech
“In biotech, all of the ideas sound amazing and most of them don’t work.” Roivant CEO Matt Gline joins Bloomberg Intelligence analyst Sam Fazeli on this episode of the Vanguards of Health Care podcast to explain how the company tries to tilt those odds through an unconventional model built around f…
48:36
Virta Health’s Push to Reverse Metabolic Disease at Scale
“We cannot fix a food problem with drugs,” says Sami Inkinen, CEO and co-founder of Virta Health. Inkinen joins Bloomberg Intelligence analyst Jonathan Palmer to explain why Virta is betting that reversing metabolic disease can become one of the most important cost and outcomes stories in health ca…
48:52